EMA Authorised: Cresemba (isavuconazole) — Basilea Pharmaceutica Deutschland GmbH

View source ↗

Summary

The EMA has authorised Cresemba (isavuconazole) for use in Aspergillosis under Basilea Pharmaceutica Deutschland GmbH, with orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis

Drugs mentioned

• Cresemba (isavuconazole)

Snippet

Status: Authorised. Therapeutic area: Aspergillosis. MAH: Basilea Pharmaceutica Deutschland GmbH. Decision date: 17/07/2025. Orphan medicine